Tech Company Financing Transactions
Apertura Gene Therapy Funding Round
On 4/26/2022, Apertura Gene Therapy landed $67 million in Series A funding from Deerfield Management Company.
Transaction Overview
Company Name
Announced On
4/26/2022
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Series A
Investors
Deerfield Management Company (Dave Greenwald)
Proceeds Purpose
To develop genetic medicines using platform technologies that address key limitations of genetic medicine delivery and expression
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
345 Park Ave South Floor 6
New York, NY 10010
United States
New York, NY 10010
United States
Phone
Website
Email Address
Not Recorded
Overview
Apertura is a biotechnology company opening opportunities for treating debilitating diseases with limited options
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 4/26/2022: Upside venture capital transaction
Next: 4/26/2022: Pyka venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs